Paratek Pharmaceuticals to merge with Optinose in a $330m deal.

Paratek Pharmaceuticals, a commercial-stage biopharmaceutical company, agreed to merge with Optinose, a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose, and throat and allergy specialists, in a $330m deal. "We have long recognized the potential of XHANCE to transform how CRS is treated. We have been exploring opportunities to make more patients and doctors aware of XHANCE and the benefits it can offer to patients suffering from this common condition. Paratek, with its robust commercial and medical capabilities, has the potential to rapidly extend awareness of XHANCE to primary care providers who treat the majority of patients with CRS. We are excited about the many ways in which this transaction creates opportunities for XHANCE to help more patients achieve better symptom control while creating near- and long-term value for Optinose’s shareholders," Ramy Mahmoud, Optinose CEO.